Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13198217 | 0.97 | HRH3 (0.36) | HRH3TBK1S1PR3JAK2NPC1 | |
| SCHEMBL13198938 | 0.95 | HRH3 (0.36) | HRH3TBK1S1PR3JAK2DYRK1A | |
| SCHEMBL12994593 | 0.95 | HRH3 (0.36) | HRH3TBK1S1PR3JAK2DYRK1A | |
| SCHEMBL12995115 | 0.95 | HRH3 (0.36) | HRH3TBK1S1PR3JAK2DYRK1A | |
| SCHEMBL12995602 | 0.95 | S1PR3 (0.36) | HRH3S1PR3NPC1CYP1A2CYP2D6 | |
| SCHEMBL10096713 | 0.95 | S1PR3 (0.36) | HRH3S1PR3NPC1CYP1A2CYP2D6 | |
| SCHEMBL12995576 | 0.94 | HRH3 (0.36) | HRH3TBK1S1PR3JAK2ACACB | |
| SCHEMBL12995489 | 0.94 | HRH3 (0.37) | HRH3TBK1JAK2NPC1CYP1A2 | |
| SCHEMBL12995574 | 0.93 | HRH3 (0.36) | HRH3TBK1S1PR3JAK2ACACB | |
| SCHEMBL12995582 | 0.93 | HRH3 (0.35) | HRH3TBK1S1PR3JAK2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772271-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | HRH3 3336/4885TBK1 1215/4885S1PR3 1968/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | HRH3 3336/4885TBK1 1215/4885S1PR3 1968/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | HRH3 3196/4885TBK1 1164/4885S1PR3 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.